THTX vs. TRML, MAZE, SNDL, PVLA, ORKA, ANAB, SVRA, SAGE, RAPP, and KOD
Should you be buying Theratechnologies stock or one of its competitors? The main competitors of Theratechnologies include Tourmaline Bio (TRML), Maze Therapeutics (MAZE), SNDL (SNDL), Palvella Therapeutics (PVLA), Oruka Therapeutics (ORKA), AnaptysBio (ANAB), Savara (SVRA), Sage Therapeutics (SAGE), Rapport Therapeutics (RAPP), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry.
Theratechnologies vs. Its Competitors
Theratechnologies (NASDAQ:THTX) and Tourmaline Bio (NASDAQ:TRML) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.
In the previous week, Tourmaline Bio had 4 more articles in the media than Theratechnologies. MarketBeat recorded 7 mentions for Tourmaline Bio and 3 mentions for Theratechnologies. Tourmaline Bio's average media sentiment score of 1.21 beat Theratechnologies' score of 0.18 indicating that Tourmaline Bio is being referred to more favorably in the news media.
Theratechnologies has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500.
Tourmaline Bio has a consensus target price of $50.14, suggesting a potential upside of 99.77%. Given Tourmaline Bio's higher possible upside, analysts clearly believe Tourmaline Bio is more favorable than Theratechnologies.
91.9% of Tourmaline Bio shares are owned by institutional investors. 13.0% of Tourmaline Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Theratechnologies has higher revenue and earnings than Tourmaline Bio. Theratechnologies is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.
Tourmaline Bio has a net margin of 0.00% compared to Theratechnologies' net margin of -10.85%. Theratechnologies' return on equity of 0.00% beat Tourmaline Bio's return on equity.
Summary
Tourmaline Bio beats Theratechnologies on 9 of the 15 factors compared between the two stocks.
Get Theratechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding THTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Theratechnologies Competitors List
Related Companies and Tools
This page (NASDAQ:THTX) was last updated on 9/5/2025 by MarketBeat.com Staff
Free THTX Stock Alerts